Found 27 Gliomas trials
A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
ONC201 in recurrent high-grade glioma
This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment …
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Primary Objectives Cohort 1: To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when administered with cemiplimab among recurrent malignant glioma participants. Cohort 2: To determine if neoadjuvant immune checkpoint blockade (ICB) with ASP8374, cemiplimab and the combination of ASP8374 plus cemiplimab will induce …
Study to evaluate drug BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
This study is being done to determine how well the study drug, BGB-290, gets into the brain tumor and to confirm if we can continuously and safely give BGB-290 and temozolomide as a combination treatment after surgery. We are testing a dose of temozolomide once a day combined with the …
A biospecimen collection study to evaluate the pharmacokinetic pharmacodynamic and resistance profile to trametinib and dabrafenib in BRAF-V600E mutated recurrent gliomas
The outlined research study is not of therapeutic intent, involving only the collection of blood, cerebrospinal fluid, and tissue samples to evaluate pharmacokinetics and resistance.
A Phase 2 Trial Of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition In Recurrent IDH-Mutant Glioma
The purpose of this research study will be to evaluate the safety and effectiveness of two investigational drugs, All-trans retinoic acid (ATRA) and Retifanlimab (anti-PD1 monoclonal antibody), in treating recurrent IDH-mutant gliomas. Objective radiographic response (CR + PR + MR) using Response Assessment in Neuro-Oncology (RANO) criteria by measurable disease …
ONC-108
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Test 20260407-1
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Test 20260407-1
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
API Push Not Cancer Study
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
API Push Trial without Cancer condition at attribute
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Please choose between Voice or SMS based delivery of verification code
or